Driving the Translation of Scientific Insights Into Clinical Practice: From "Nice to Know" to "Need to Implement"
Event 2021 - Speakers & Topics
Ahmad Awada, Professor, Head of the Oncology Medicine Dept., Jules Bordet Cancer Institute Brussels, Belgium
Utilizing Targeted Therapy and Immunotherapy Earlier: What is the Rationale and How Cancer Patients Benefit
Marcela Maus, Assistant Professor, Medicine, Harvard Medical School, Director of Cellular Immunotherapy, Cancer Center, Massachusetts General Hospital, USA
Translating Next Generation Cell Therapies into the Clinic: What are Hurdles and How Can We Overcome These?
Andrew Sewell, Professor, Division of Infection and Immunity. Mechanisms of Immunity Theme Lead, Systems Immunity Research Institute, Cardiff University, UK
New T-cell Receptors and Targets by Dissection of Successful Cancer Immunotherapy.
Emile Voest, Professor of Medical Oncology, Medical Director of The Netherlands Cancer Institute, NL
Bringing Precision Medicine to Patients: Lessons Learned from DRUP Trial and the Way Forward.
Jérôme Galon, Director of Research at INSERM, Head of INSERM laboratory for Integrative Cancer Immunology, Cordeliers Research Center, Paris, France
The Interplay between Tumor Evolution and Tumor Immunology: Implications on Progression and Treatment.
Event 2021 - Moderators & Panelists from Norway
Moderator, Session 1: Jon Amund Kyte, Head, Department of Experimental Cancer Treatment, Oslo University Hospital Comprehensive Cancer Center, Oslo Panelists, Session 1: Halfdan Sørbye, Professor, Department of Oncology, Haukeland University Hospital, Bergen Anne Hansen Ree, Professor of Oncology, Akershus University Hospital, University of Oslo Nina Jebsen, Associate Professor, Dept. of Clinical Science, Haukeland University Hospital, Bergen Emiel A.M. Janssen, Professor, University of Stavanger, Dept. of Pathology, Stavanger University Hospital, Stavanger
Moderator, Session 2: Johanna Olweus, Professor, University of Oslo, Head of Department of Cancer Immunology, Oslo University Hospital Panelists, Session 2: Jochen Buechner, Senior Consultant Pediatric Hematology & Oncology, Oslo University Hospital Ingerid Weum Abrahamsen, Senior Consultant Hematology, Department of Hematology, Oslo University Hospital
Moderator, Session 3: Sigrid Bratlie, Special Advisor, Norwegian Cancer Society Panelists, Session 3: Åslaug Helland, Professor, Head of Research Division of Cancer Medicine, Oslo University Hospital Ali Areffard, Disease Area Specialist Immuno-Oncology, Bristol Myers Squibb Siri Børø, Medical Specialist Oncology, Merck